| Item | Evidence/Numbers | Source (with DOI/URL when available) | Pub year |
|---|---|---|---|
| Definition | Rare immune-mediated disorder causing diffuse autonomic failure involving sympathetic, parasympathetic, and enteric systems; often considered an antibody-mediated autonomic ganglionopathy/ganglionopathy phenotype (pqac-00000003, pqac-00000004, pqac-00000006) | Iodice et al., *Neurology* doi:10.1212/WNL.0b013e3181a92b52 https://doi.org/10.1212/WNL.0b013e3181a92b52; Golden & Vernino, *Clin Auton Res* doi:10.1007/s10286-019-00611-1 https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., *Int J Mol Sci* doi:10.3390/ijms25042296 https://doi.org/10.3390/ijms25042296 | 2009; 2019; 2024 |
| Core autoantigen / autoantibody | Ganglionic nicotinic acetylcholine receptor (gAChR), especially α3-containing receptor; antibodies bind mainly α3 subunit, usually in α3β4 receptor complex (pqac-00000004, pqac-00000006, pqac-00000023) | Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., https://doi.org/10.3390/ijms25042296; Vernino et al., *Neurology* doi:10.1212/WNL.50.6.1806 https://doi.org/10.1212/WNL.50.6.1806 | 2019; 2024; 1998 |
| Pathogenic mechanism | Proposed 3-step model: antibody binding → receptor internalization/degradation → functional blockade; patient IgG reduces ganglionic AChR currents; passive transfer in mice reduces EPSPs (pqac-00000006, pqac-00000027) | Nakane et al., https://doi.org/10.3390/ijms25042296; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1 | 2024; 2019 |
| Seropositivity rate | About 50% of clinically suspected AAG patients are seropositive for gAChR antibodies; seronegative disease remains recognized (pqac-00000000, pqac-00000003, pqac-00000004, pqac-00000018) | Mohapatra et al., *Ann Indian Acad Neurol* doi:10.4103/aian.aian_394_24 https://doi.org/10.4103/aian.aian_394_24; Iodice et al., https://doi.org/10.1212/WNL.0b013e3181a92b52; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304 | 2024; 2009; 2019; 2018 |
| Antibody threshold: classic RIPA positivity | Upper lab limit reported as 0.05 nmol/L in one major clinical series; antibody-positive AAG defined at or above this threshold (pqac-00000001, pqac-00000007) | Iodice et al., https://doi.org/10.1212/WNL.0b013e3181a92b52; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1 | 2009; 2019 |
| Antibody titer interpretation | >0.20 nmol/L fairly specific for AAG; high titers correlate with more severe dysautonomia/cholinergic failure; ≥1.0 nmol/L associated with severe pan-dysautonomia; <0.2 nmol/L often nonspecific and seen in ~2%–4% of healthy people (pqac-00000007, pqac-00000000) | Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Mohapatra et al., https://doi.org/10.4103/aian.aian_394_24 | 2019; 2024 |
| LIPS assay thresholds | Anti-gAChRα3 A.I. cutoff 1.0: sensitivity 50.0%, specificity 100%; anti-gAChRβ4 A.I. cutoff 1.0: sensitivity 10.0%, specificity 100% (pqac-00000017) | Nakane et al., *Expert Rev Neurother* doi:10.1080/14737175.2018.1540304 https://doi.org/10.1080/14737175.2018.1540304 | 2018 |
| Typical demographics | Middle age predominance; mean ages reported ~45–61 years with ~2:1 female predominance; in Koay cohort median onset 54 years, 54% female; in Japanese cohort mean age 60±18 years (43M/37F) (pqac-00000004, pqac-00000011, pqac-00000017) | Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Koay et al., *Ann Neurol* doi:10.1002/ana.26018 https://doi.org/10.1002/ana.26018; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304 | 2019; 2021; 2018 |
| Onset / course | Often acute or subacute; spontaneous but usually incomplete recovery in ~one-third; in seropositive Japanese cohort gradual onset predominated 62/80 (78%), antecedent events 13/80 (16%) (pqac-00000003, pqac-00000004, pqac-00000014, pqac-00000018) | Iodice et al., https://doi.org/10.1212/WNL.0b013e3181a92b52; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304 | 2009; 2019; 2018 |
| Common feature: orthostatic hypotension / intolerance | Most common presenting/autonomic feature; 64/80 (80%) in seropositive Japanese cohort; initial symptom in 50/80 (62.5%); all 13/13 in Koay cohort had cardiovascular autonomic failure with orthostatic hypotension (pqac-00000014, pqac-00000011, pqac-00000019) | Nakane et al., https://doi.org/10.1080/14737175.2018.1540304; Koay et al., https://doi.org/10.1002/ana.26018 | 2018; 2021 |
| Common feature: lower GI dysmotility | Lower GI symptoms in 59/80 (74%) seropositive cases; GI dysfunction is a core cholinergic manifestation (pqac-00000014, pqac-00000004, pqac-00000015) | Nakane et al., https://doi.org/10.1080/14737175.2018.1540304; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1 | 2018; 2019 |
| Common feature: urinary dysfunction | Urinary retention 9/11 (82%); catheterisation required in 5/13 (38%); abnormal uroflowmetry in 6/8 (75%) in Koay cohort (pqac-00000008, pqac-00000012) | Koay et al., https://doi.org/10.1002/ana.26018 | 2021 |
| Common feature: pupillary dysfunction | Pupillary dysfunction 21/80 (26%) in Japanese cohort; in Koay cohort impaired pupillary constriction 12/13 (92%), cholinergic supersensitivity in 5/5 tested, ptosis 4/13 (31%) (pqac-00000014, pqac-00000008, pqac-00000011) | Nakane et al., https://doi.org/10.1080/14737175.2018.1540304; Koay et al., https://doi.org/10.1002/ana.26018 | 2018; 2021 |
| Common feature: secretomotor dysfunction | Reduced lacrimation 9/11 (82%), reduced salivary production 6/8 (75%), impaired sweat production 7/8 (88%) in Koay cohort; sicca/anhidrosis also emphasized in reviews (pqac-00000008, pqac-00000012, pqac-00000004) | Koay et al., https://doi.org/10.1002/ana.26018; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1 | 2021; 2019 |
| Extra-autonomic manifestations | Extra-autonomic involvement common: 67/80 (84%) in seropositive Japanese cohort; sensory disturbance/numbness 37/80 (46%); concurrent autoimmune disease in 25/80 (31%); tumors in 11/80 (14%); in Koay cohort other autoimmune diseases in 8/13 (62%) (pqac-00000014, pqac-00000016, pqac-00000011) | Nakane et al., https://doi.org/10.1080/14737175.2018.1540304; Koay et al., https://doi.org/10.1002/ana.26018 | 2018; 2021 |
| Catecholamine / imaging biomarkers | Resting plasma catecholamines often low; in Koay cohort plasma noradrenaline mostly 100–200 pg/ml with absent tilt rise; reduced cardiac 123I-MIBG uptake in ~80% of Japanese AAG cohort, and uptake may improve after immunotherapy (pqac-00000002, pqac-00000011, pqac-00000015) | Nakane et al., https://doi.org/10.3390/ijms25042296; Koay et al., https://doi.org/10.1002/ana.26018; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304 | 2024; 2021; 2018 |
| CSF findings | Elevated CSF protein in 48% and albuminocytologic dissociation in 37% in review summary; another review cites albuminocytologic dissociation in ~40% (pqac-00000002, pqac-00000000) | Nakane et al., https://doi.org/10.3390/ijms25042296; Mohapatra et al., https://doi.org/10.4103/aian.aian_394_24 | 2024; 2024 |
| Core diagnostic tests | History and time-course; autonomic reflex screen; head-up tilt; Valsalva; HR response to deep breathing; QSART/TST/sweat testing; plasma catecholamines; Schirmer/Saxon tests; pupillometry; uroflowmetry; GI motility studies; skin biopsy; 123I-MIBG scintigraphy; gAChR antibody testing by RIPA/CBA/LIPS (pqac-00000001, pqac-00000002, pqac-00000015, pqac-00000019) | Iodice et al., https://doi.org/10.1212/WNL.0b013e3181a92b52; Nakane et al., https://doi.org/10.3390/ijms25042296; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304; Koay et al., https://doi.org/10.1002/ana.26018 | 2009; 2024; 2018; 2021 |
| Preferred antibody assays | RIPA or live cell-based assay considered most accurate in recent review; LIPS also used with high specificity in Japanese studies (pqac-00000002, pqac-00000017) | Nakane et al., https://doi.org/10.3390/ijms25042296; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304 | 2024; 2018 |
| First-line immunotherapy | IVIG and plasma exchange generally regarded as first-line; corticosteroids commonly added/used in pulse regimens (pqac-00000005, pqac-00000015, pqac-00000018) | Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304 | 2019; 2018 |
| Maintenance / refractory treatment | Prednisolone, azathioprine, mycophenolate mofetil, rituximab used for sustained control or refractory disease; evidence mainly case reports/series (pqac-00000005, pqac-00000015, pqac-00000007) | Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304 | 2019; 2018 |
| Quantitative response biomarkers after immunotherapy | In Koay cohort, orthostatic intolerance ratio improved 33.3 [17.8–61.3] → 5.2 [1.4–8.2] (P=.007); HR response to deep breathing 1.5 → 4.5 (P=.02); pupillary constriction 12.0% → 19.0% (P=.02); saliva 0.01 → 0.08 g/min (P=.03); COMPASS-31 52 → 17 (P=.03) (pqac-00000012, pqac-00000020) | Koay et al., https://doi.org/10.1002/ana.26018 | 2021 |
| Clinical trial landscape | Very limited prospective evidence; one identified interventional IVIG study: NCT01522235, completed, phase 2/3, enrollment 6 (clinicaltrials.gov result in tool output) (pqac-00000003) | Beth Israel Deaconess Medical Center trial listing: NCT01522235 | — |


*Table: This table compiles high-yield clinical and mechanistic facts about autoimmune autonomic ganglionopathy, including antibody biology, phenotype frequencies, diagnostics, and treatment patterns. It is designed as a compact evidence summary for rapid knowledge-base ingestion.*